Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease
Cost-Utility Analysis published in the Expert Review of Pharmacoeconomics and Outcomes ResearchMENLO PARK, Calif., July 30, 2025 (GLOBE NEWSWIRE) --...